CLINICAL TRIALS PROFILE FOR DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

All Clinical Trials for Dextrose 5% And Lactated Ringer's In Plastic Container

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00113685 ↗	Hypertonic Saline With Dextran for Treating Hypovolemic Shock and Severe Brain Injury	Completed	National Heart, Lung, and Blood Institute (NHLBI)	N/A	2003-04-01	The purpose of this study is to evaluate the clinical outcome of patients following blunt traumatic injury with hypovolemic shock, who receive either lactated ringer's solution or hypertonic saline with dextran (HSD) resuscitation; also, to focus specifically on neurologic outcome in patients with brain injury and on the effect of HSD resuscitation on inflammatory cell responsiveness.
NCT00113685 ↗	Hypertonic Saline With Dextran for Treating Hypovolemic Shock and Severe Brain Injury	Completed	University of Washington	N/A	2003-04-01	The purpose of this study is to evaluate the clinical outcome of patients following blunt traumatic injury with hypovolemic shock, who receive either lactated ringer's solution or hypertonic saline with dextran (HSD) resuscitation; also, to focus specifically on neurologic outcome in patients with brain injury and on the effect of HSD resuscitation on inflammatory cell responsiveness.
NCT00181077 ↗	Hypertonic Saline Use in Preeclampsia	Completed	Johns Hopkins University	Phase 1	2003-06-01	To compare hypertonic saline to Lactated Ringer's solution and assess whether one speeds up the process of getting rid of extra body water faster in women with preeclampsia.
NCT00311519 ↗	A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects	Completed	Halozyme Therapeutics	Phase 4	2005-11-01	The purpose of this research study to test the effectiveness of a study medication to increase how fast a solution called lactated Ringer's is absorbed when put under the skin subcutaneously. The medication to be studied is an enzyme called hyaluronidase, and is a human recombinant form of the enzyme. The drug company name for this medication is Hylenex. Hylenex was currently an investigational medication at the initiation of the study, but received FDA approval during the study. An investigational medication is a medication or formulation of a medication that is not approved by the United States Food and Drug Administration for use in this country but may be used in studies such as this one.

Clinical Trial Conditions for Dextrose 5% And Lactated Ringer's In Plastic Container

Condition Name

Condition Name for Dextrose 5% And Lactated Ringer's In Plastic Container
Intervention	Trials
Cesarean Section	6
Hypotension	6
Anesthesia	5
Cesarean Delivery	4

Condition MeSH

Condition MeSH for Dextrose 5% And Lactated Ringer's In Plastic Container
Intervention	Trials
Hypotension	18
Pancreatitis	12
Hemorrhage	10
Pain, Postoperative	10

Clinical Trial Locations for Dextrose 5% And Lactated Ringer's In Plastic Container

Trials by Country

Trials by Country for Dextrose 5% And Lactated Ringer's In Plastic Container
Location	Trials
Egypt	45
United States	36
China	16
Korea, Republic of	5
Brazil	4

Trials by US State

Trials by US State for Dextrose 5% And Lactated Ringer's In Plastic Container
Location	Trials
Connecticut	4
Illinois	4
California	3
Pennsylvania	3
Ohio	2

Clinical Trial Progress for Dextrose 5% And Lactated Ringer's In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Dextrose 5% And Lactated Ringer's In Plastic Container
Clinical Trial Phase	Trials
PHASE4	5
PHASE3	4
PHASE2	1

Clinical Trial Status

Clinical Trial Status for Dextrose 5% And Lactated Ringer's In Plastic Container
Clinical Trial Phase	Trials
Completed	69
Recruiting	30
Not yet recruiting	29

Clinical Trial Sponsors for Dextrose 5% And Lactated Ringer's In Plastic Container

Sponsor Name

Sponsor Name for Dextrose 5% And Lactated Ringer's In Plastic Container
Sponsor	Trials
Ain Shams University	10
Cairo University	10
Mansoura University	5

Sponsor Type

Sponsor Type for Dextrose 5% And Lactated Ringer's In Plastic Container
Sponsor	Trials
Other	267
Industry	19
NIH	4

Last updated: April 28, 2026

Clinical trials update, market analysis and projection: Dextrose 5% and Lactated Ringer’s in plastic container

What clinical-trial evidence exists for “Dextrose 5% and Lactated Ringer’s in plastic container”?

No complete and verifiable clinical-trials dataset can be produced from the information provided. The name indicates a compounded or co-administered IV solution product class (D5 + Lactated Ringer’s) delivered in a plastic container, but it does not specify a proprietary brand, manufacturer, dosage form beyond container type, country, regulatory listing, or the exact investigational formulation used in trials. As a result, a complete clinical-trials update with trial IDs, endpoints, and status cannot be compiled without risking inaccurate attribution.

How big is the market for Dextrose 5% and Lactated Ringer’s IV solutions?

A complete market sizing answer cannot be produced from the information provided. The market for this specific combination depends on: (1) whether it is marketed as a single finished combination product versus a compounding practice, (2) geography (US vs EU vs other), (3) container type (plastic bag versus bottle), and (4) regulatory status (approved finished drug product versus hospital compounded admixture). Without those specifics, any numeric market size would be speculative.

What projections are possible for 5% dextrose and lactated Ringer’s in plastic containers?

A complete projection requires at least one of: (a) an underlying epidemiology-and-utilization model with quantified IV-fluid demand by indication, (b) a validated market segment definition from a reputable dataset (IMS, IQVIA, GlobalData, etc.), or (c) observable sales signals by SKU and container form. None are provided, so an evidence-based projection cannot be produced.

What can be quantified right now for market decision-making?

Only high-level, non-quantified commercialization drivers can be stated without fabricating numbers. Still, no actionable projections or market shares can be delivered without a defined market scope.

---

Decision-grade framework: what to validate before underwriting R&D or investment

The drug phrase you provided is best treated as a product definition that must be mapped to a specific, trackable regulatory and commercial construct. For underwriting or pipeline diligence, the following items must exist and be consistent across sources:

1. Exact formulation listing

   • Does the marketed product contain “Dextrose 5%” plus “Lactated Ringer’s” as a single finished IV solution, or is it a compounding practice from separate components?
   • Is the formulation stated as “D5 in LR” (or similar) with specific electrolyte and dextrose concentrations?

2. Regulatory construct

   • Finished product authorization (e.g., US NDA/BLA/ANDA, EU marketing authorization) versus “compounded admixture” classification.
   • Reference to pharmacopoeial or compendial standard (if applicable), and container-grade details.

3. Container SKU definition

   • “Plastic container” must map to an actual SKU line (e.g., flexible VIAFLEX-type bag vs rigid bottle).
   • Packaging strength, fill volume, and distribution channel must be traceable.

4. Use case and setting

   • Indications drive utilization: maintenance fluids, resuscitation adjunct, perioperative hydration, or specific patient populations.
   • Hospital versus retail outpatient mix affects repeatability and contracting behavior.

5. Comparable spend benchmarks

   • Pricing benchmarks should use like-for-like container size and formulation.
   • Forecasting should follow payor contracting patterns and tender cycles where hospital procurement dominates.

---

Key Takeaways

• A clinical-trials update with trial-level proof cannot be produced from the provided product description.
• A quantified market size and numeric projection cannot be produced without a defined, trackable regulatory and commercial SKU scope.
• Before any R&D or investment underwriting, the formulation must be mapped to a finished-product listing (or explicitly confirmed as a compounded practice) and a specific plastic-container SKU.

---

FAQs

1. Is “Dextrose 5% and Lactated Ringer’s in plastic container” a single drug product or a compounding mix?
   It can be either depending on the country and manufacturer listing. Without a specific regulatory listing, the distinction cannot be confirmed.

2. Why does container type (plastic) matter for market and clinical interpretation?
   Plastic container SKUs can differ by material, fill volume, and distribution channel, which affects tendering and comparability in sales data.

3. What endpoints typically matter in IV-fluid comparative clinical trials?
   Common endpoints include fluid balance, time to normalization of electrolytes, safety parameters (e.g., osmolarity-related issues), and adverse event rates.

4. What drives demand for dextrose plus lactated Ringer’s fluids?
   Hospital utilization patterns for maintenance and perioperative hydration, patient mix, and procurement contracts.

5. What is the fastest path to a usable market forecast?
   Map the formulation to a finished-product SKU with country-specific regulatory approval, then use historical procurement or sales data tied to that SKU and container size.

---

References

[1] No sources cited.